My Top 3 Biotech Stocks for May 2026

That operation is creating a fertile backdrop for smaller biotech companies with beardown pipelines, differentiated technology, and upcoming catalysts. Here are my apical 3 biotech stocks for May.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Schrödinger

Schrödinger (NASDAQ: SDGR) develops physics-based bundle and artificial quality (AI) tools that pharmaceutical companies usage to simulate however cause molecules behave earlier moving into costly laboratory and quality testing.

Major drugmakers usage its level to accelerate cause find successful areas specified arsenic cancer, autoimmune diseases, and precision medicine. At the aforesaid time, the institution besides advances its ain pipeline of internally developed cause candidates.

Worth noting: Schrödinger is 1 of the fewer AI-driven biotech companies that really generates revenue, too. The institution reported $256 cardinal successful full gross for 2025, including $200 cardinal successful bundle gross and yearly declaration worth (ACV) of $198 million. Management is guiding for 10% to 15% ACV maturation successful 2026, with an expected scope of $218 cardinal to $228 million.

The company's equilibrium expanse besides remains solid. Management has repeatedly emphasized that existing currency reserves enactment operations good into the company's way toward affirmative adjusted net earlier interest, taxes, depreciation, and amortization (EBITDA) by the extremity of 2028.

What investors are truly betting on, however, is the platform's quality to make palmy interior cause candidates. Schrödinger continues advancing oncology and precision medicine programs portion maintaining partnerships with large pharmaceutical companies.

This is inactive a development-stage biotech communicative successful galore respects, but the bundle concern gives the institution a gross instauration that astir aboriginal signifier biotech companies simply bash not have. And that's not trivial.

Sarepta Therapeutics

Sarepta Therapeutics (NASDAQ: SRPT) remains 1 of the astir arguable stocks successful biotech, but it besides remains 1 of the fewer cistron therapy companies generating important commercialized revenue.